The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.
CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor.
Trispecific T-cell Engager (TriTE) offering full activation signal to T cell through co-engagement of TCR/CD3 and co-stimulatory receptor
NK activation receptor agonists or inhibitory receptor antagonists for effective tumor killing
Marcrophage revitalize agents to enhance innate as well as adaptive immunity for cancer treatment
2024年6月3日,惠和生物在自免疾病领域的IND申请已正式获得国家药品监督管理局药品审评中心(CDE)受理!
2024年5月24日下午,惠和生物组织的闭门学术研讨沙龙成功举办,与会嘉宾们围绕着“细胞免疫、新药与临床转化”的主题进行分享、讨论和交流。
惠和生物凭借2023年度在生物医药创新领域的积极创新研究成果和临床研究表现,跻身浦东新区2023年度创新创业20强行列,荣获“2023年度浦东新区创新创业奖”。本次获奖是对惠和生物扎根浦东、多年深耕和坚持本土原创创新的又一次认可与鼓励。惠和生物首席运营官曾立博士受邀出席表彰活动并代表惠和生物领取荣誉奖项。